Abstract 15112: Characteristics and Clinical Outcomes of Patients With Sarcoidosis Admitted for ST-Elevation Myocardial Infarction

Abstract

Background: Multisystem involvement is often seen in sarcoidosis. This study aims to explore the characteristics and clinical outcomes following hospitalization for ST-elevation myocardial infarction (STEMI) in patients with sarcoidosis when compared to patients without sarcoidosis. Methods: Patients with and without sarcoidosis admitted for STEMI were identified and compared from the 2016-2020 National Inpatient Sample (NIS) database whilst adjusting for confounders via logistic regression models. Results: A total of 851290 patients hospitalized with a primary diagnosis of STEMI between 1 st January 2016 to 31 st December 2020 were identified. Around 1215 (0.1%) had a diagnosis of sarcoidosis consisting of 58.4% males. When compared to patients without sarcoidosis, patients with sarcoidosis had a longer mean length of stay (LOS: 4.76 vs. 4.01 days, p<0.01), a greater prevalence of diabetes (42.4% vs. 32.4%, p<0.01), cirrhosis (1.6% vs. 0.5%, p<0.01), depression (9.1% vs. 6.7%, p<0.01), peripheral vascular disease (7.8% vs. 5.1%, p<0.01), obesity (24.3% vs. 17.8%, p<0.01), chronic kidney disease (25.9% vs. 13.1%, p<0.01) and prior stroke (7.4% vs. 5.2%, p<0.01). However, patients without sarcoidosis had a higher incidence of percutaneous coronary intervention (PCI) (79.8% vs. 75.3%, p<0.01), smoking (52% vs. 35.4%, p<0.01), drug abuse (2.8% vs. 1.2%, p<0.01) and alcohol abuse (3.5% vs. 2.1%, p<0.01) (Table 1A). Moreover, patients with sarcoidosis were less likely to have cardiogenic shock during their hospitalization (12.3% vs. 13.7%, aOR 0.768, 95% CI 0.636-0.927, p<0.01). No statistically significant differences were seen for CABG or PCI use, events of Acute Kidney Injury, acute ischemic stroke and death (Table 1AB). Conclusion: Patients with sarcoidosis admitted for STEMI had a longer length of stay and fewer cardiogenic shock incidence when compared to patients without sarcoidosis. Complications and mortality was otherwise comparable.